CIBC to Issue 7.000% NVCC AT1 Limited Recourse Capital Notes
The LRCNs will bear interest at a rate of 7.000% annually, payable quarterly, for the initial period ending on, but excluding, October 28, 2030. Thereafter, the interest rate on the LRCNs will reset every five years at a rate equal to the prevailing 5-year U.S. Treasury Rate plus 3.000%. The LRCNs will mature on October 28, 2085. The expected closing date of the offering is July 14, 2025.
In connection with the issuance of the LRCNs, CIBC will issue Non-Cumulative 5-Year Fixed Rate Reset Class A Preferred Shares Series 62 (Non-Viability Contingent Capital (NVCC)) (the "Series 62 Shares") to be held by Computershare Trust Company of Canada as trustee of CIBC LRCN Limited Recourse Trust (the "Limited Recourse Trust"). In case of non-payment of interest on or principal of the LRCNs when due, the recourse of each LRCN holder will be limited to that holder's proportionate share of the Limited Recourse Trust's assets held in respect of the LRCNs, which will consist of Series 62 Shares except in limited circumstances.
CIBC may redeem the LRCNs on October 28, 2030 and on each January 28, April 28, July 28 and October 28 thereafter with the prior written approval of the Superintendent of Financial Institutions (Canada), in whole or in part on not less than 10 days' nor more than 60 days' prior notice.
The net proceeds to CIBC from the sale of the LRCNs will be used for general corporate purposes, which may include the redemption of outstanding capital securities of CIBC, and/or the repayment of other outstanding liabilities of CIBC.
The joint book-running managers for the offering are CIBC World Markets Corp., Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC.
A registration statement relating to the offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is effective. The offering is being made only by means of a prospectus supplement and a base prospectus. Copies of the prospectus supplement and the base prospectus for the offering may be obtained free of charge by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, the prospectus supplement and accompanying base prospectus may be obtained by calling CIBC World Markets Corp. toll-free at (800) 282-0822; Barclays Capital Inc. toll-free at (888) 603-5847; BofA Securities, Inc. toll-free at (800) 294-1322; Citigroup Global Markets Inc. toll-free at (800) 831-9146; or J.P. Morgan Securities LLC collect at (212) 834-4533.
This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any offer, solicitation or sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CIBC
CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at www.cibc.com/ca/media-centre.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dynamic is setting the stage for a "flight to quality" among investors, who are now more than ever looking for innovative leaders with strong pipelines and clear paths to regulatory execution, a key milestone that can separate a promising biotech from a potential breakthrough like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB). According to a report from Global Market Insights, the global oncology market was estimated at US$345.1 billion in 2025, and while growing at an impressive 10.8% CAGR, is projected to reach US$866.1 billion by 2034 — with $377.1 billion of that coming from the USA alone. Even more optimistic is a report from Vision Research Reports, which sees the global cancer drug sector surpassing US$900 billion in sales by 2034. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) for its flagship asset, pelareorep. In its latest Q2 2025 report, the company confirmed it has begun formal discussions with the U.S. Food and Drug Administration (FDA) aimed at finalizing a pivotal study design, with trial start-up activities expected to begin as early as Q4 2025. For investors and potential partners, this represents a clear transition from promising clinical data to potential regulatory approval in one of medicine's most challenging cancer types. "We have turned the corner from proof-of-concept studies and will be sprinting toward regulatory clarity for the remainder of the year," said Jared Kelly, CEO of Oncolytics. "As we shore up our intellectual property, get a clear registration path for pelareorep, and allow our GOBLET data to mature, we will establish our position as the only platform immunotherapy in gastrointestinal tumors." The strategic focus on mPDAC reflects both compelling clinical results and a significant market opportunity. Pelareorep is a systemically delivered oncolytic virus designed to convert immunologically "cold" tumors—those typically invisible to the immune system—into "hot" tumors that can respond to immunotherapy. In first-line pancreatic cancer studies, pelareorep-based regimens have demonstrated a notable 21.9% two-year overall survival rate, compared to a 9.2% historical benchmark for standard chemotherapy alone. Even more compelling, when pelareorep was combined with chemotherapy and a checkpoint inhibitor, researchers recorded a 62% objective response rate—particularly significant given that checkpoint inhibitors are not currently approved for use in this indication. These results stem from pelareorep's dual mechanism: it both replicates within cancer cells and activates the body's immune response against tumors. "This robust data set, amassed from several studies in cancers that have historically resisted immunotherapeutic approaches, provides definitive validation of pelareorep's immune-mediated mechanism of action," said Dr. Thomas Heineman, Chief Medical Officer of Oncolytics. "We observed tumor biopsy-confirmed virus replication, immune cell activation, and the recruitment of cytotoxic T cells into the TME—all consistent with the durable responses observed in patients with metastatic PDAC and HR+/HER2- breast cancer who were treated with pelareorep." Translational data from the GOBLET and AWARE-1 studies demonstrate how pelareorep transforms the tumor microenvironment, increasing PD-L1 expression, heightening interferon signaling, and mobilizing tumor-infiltrating lymphocytes in the blood—changes that correlate with tumor size reduction. This mechanistic validation, combined with survival data from over 1,100 patients across multiple studies, has solidified the company's decision to prioritize this indication. Oncolytics' execution-focused strategy is being led by Jared Kelly and Andrew Aromando, who both played key roles in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson. Kelly was appointed CEO earlier this year, while Aromando recently joined as Chief Business Officer. In line with their focus on capital efficiency, the company has terminated its At-the-Market and Equity Line of Credit facilities, citing sufficient resources to advance key milestones without near-term shareholder dilution. Regulatory advantages are already in place to accelerate development. Pelareorep holds Fast Track and Orphan Drug designations for pancreatic cancer from the FDA, meaning the agency has already recognized both the drug's potential and the serious unmet need in this patient population. These statuses streamline review processes and enhance the program's attractiveness to potential pharmaceutical partners. The context underscores the opportunity: pancreatic cancer remains one of the deadliest common cancers, with a five-year survival rate of less than 14%. Unlike other cancers where immunotherapies have transformed treatment, mPDAC has largely resisted immunotherapeutic approaches—making pelareorep's immune-activating mechanism particularly promising for this underserved patient population. Back in July, Oncolytics hosted a key opinion leader event featuring gastrointestinal cancer experts who reviewed survival outcomes for patients and biomarker validation. The expert panel reinforced the view that pelareorep's mechanism of activating innate and adaptive immune responses is both biologically sound and commercially relevant for first-line mPDAC treatment. With this latest milestone, Oncolytics is entering a phase where FDA feedback will shape both clinical plans and potential commercial partnerships. If the agency accepts the company's proposed trial framework centered on an overall survival endpoint, the resulting study could provide definitive proof of pelareorep's market potential in mPDAC. The company expects to provide an updated clinical timeline in Q3 2025, with trial start-up activities potentially beginning as early as Q4 2025. With compelling survival data, regulatory designations in place, and an experienced leadership team driving execution, Oncolytics is positioning pelareorep for a pivotal test in one of oncology's most challenging and underserved markets. In other recent industry developments and happenings in the market include: ProPhase Labs, Inc. (NASDAQ: PRPH) announced it received a U.S. patent for its BE-Smart test that can detect early signs of Barrett's esophageal cancer, a deadly disease that kills most patients because it's usually caught too late. The test works with simple brush and forceps biopsies and achieved over 95% accuracy in clinical testing, potentially allowing doctors to catch this cancer when it's still treatable. "This achievement, coming on the heels of our BE-Smart ™ validation demonstrating greater than a 95% technical success rate and dual compatibility with both brush and forceps biopsies, solidifies our leadership in medical innovation and brings us one step closer to transforming early detection and treatment strategies for this serious condition," said Ted Karkus, CEP of ProPhase. "With this newly issued patent, we believe we are well positioned to accelerate commercialization and broaden clinical access to BE-Smart." ProPhase's breakthrough could save thousands of lives by identifying patients at high risk for esophageal cancer before the disease becomes incurable, representing a major advancement in early cancer detection. IO Biotech, Inc. (NASDAQ: IOBT) recently announced that its experimental cancer vaccine (Cylembio) meaningfully extended the time before advanced melanoma patients got worse, with patients living 19.4 months without disease progression compared to 11 months for those on standard treatment alone. The vaccine works by training the immune system to attack both cancer cells and the cells that help tumors hide from treatment, and it showed particularly strong results in patients whose tumors were PD-L1 negative and unlikely to respond to current immunotherapies. "In this study, we observed a highly encouraging improvement in progression free survival and consistent trend in overall survival in patients treated with Cylembio," said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. "The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data." IO Biotech plans to meet with the FDA this fall to discuss approval for this treatment that could become a new standard of care for the deadliest form of skin cancer. Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) reported progress on its experimental breast cancer pill called palazestrant, which is designed to completely block estrogen signals that fuel most breast cancers and is currently being tested in two large Phase 3 trials expected to finish in 2026. "Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026," said Sean P. Bohen, M.D., Ph.D., President and CEO of Olema. "Palazestrant's demonstrated activity and combinability with multiple compounds offers the potential for it to become a best-in-class, backbone endocrine therapy for metastatic breast cancer." The company is also developing OP-3136, a pill that targets a different pathway cancer cells use to grow and spread, with early results expected in 2026. Olema's drugs are designed to work where current treatments fail, potentially offering hope to the thousands of breast cancer patients whose tumors eventually become resistant to existing therapies. PDS Biotechnology Corporation (NASDAQ: PDSB) reported promising results from a colorectal cancer study where its experimental treatment achieved impressive response rates, leading to expansion of the trial to treat more patients with this hard-to-treat cancer. "Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial," said Frank Bedu-Addo, Ph.D., President and CEO of PDS Biotech. "We look forward to publishing the full data set for this trial later this year, as we continue to progress our VERSATILE-003 trial, the only registrational stage trial specifically targeting HPV16-positive HNSCC patients." The company's lead program targets head and neck cancers caused by HPV, the same virus that is a major cause of cervical cancer, and is currently being tested in the only late-stage trial specifically designed for these patients. PDS Biotech's approach uses its immune-boosting technology to help the body's natural defenses better recognize and destroy cancer cells, potentially offering new hope for patients with limited treatment options. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Toronto FC gets US$175,000 in general allocation money from Inter Miami
TORONTO – Toronto FC and Inter Miami traded for roster resources on Thursday. TFC got US$175,000 in general allocation money for this year in the deal. In return, Inter Miami received an international roster spot for this season. It's the latest in a series of similar deals Toronto FC has made to stockpile GAM. The most recent came on Wednesday when Toronto sent midfielder Matty Longstaff to CF Montreal for forward Jules-Anthony Vilsaint and $225,000 in 2025 GAM. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. TFC will also get a conditional $50,000 in 2026 GAM from that deal, depending on Longstaff's roster status next year. This report by The Canadian Press was first published Aug. 14, 2025.
Cision Canada
2 hours ago
- Cision Canada
Crypto Treasury Revolution: How $47B Corporate Shift Creates New Investment Opportunities
Issued on behalf of CEA Industries, Inc. VANCOUVER, BC, Aug. 14, 2025 /CNW/ -- Equity Insider News Commentary – The corporate crypto revolution has moved from experiment to mainstream strategy, as public companies poured $47.3 billion into digital assets in 2025 alone, significantly outpacing ETF inflows of $31.7 billion and signaling a fundamental shift in how businesses manage their treasuries. This institutional embrace has been accelerated by regulatory clarity, with pro-crypto policies and the passage of legislation like the CLARITY Act creating a pathway for traditional corporations to treat digital assets as legitimate reserve holdings. Leading research firm DWF Ventures published comprehensive analysis showing that 14 major public companies now collectively hold $76 billion in digital assets, with $40 billion deployed in just the past year alone. The momentum shows no signs of slowing, as over 60 public companies have now confirmed cryptocurrency positions on their balance sheets, spanning everything from tech giants to entertainment companies, and pointing the market towards innovative crypto-focused companies including CEA Industries, Inc. (NASDAQ: BNC), BIT Mining Limited (NYSE: BTCM), Upexi, Inc. (NASDAQ: UPXI), Bitcoin Depot Inc. (NASDAQ: BTM), and Canaan Inc. (NASDAQ: CAN). Mordor Intelligence forecasts the global cryptocurrency market will surge from $2.96 trillion in 2025 to $7.98 trillion by 2030, representing a robust 30.1% CAGR driven by institutional adoption and regulatory frameworks. Meanwhile, Grand View Research projects the cryptocurrency infrastructure market will expand from $5.70 billion in 2024 to $11.71 billion by 2030 at a 13.1% CAGR, reflecting the growing demand for institutional-grade crypto treasury solutions that these pioneering companies are racing to capture. CEA Industries, Inc. (NASDAQ: BNC) isn't your typical cryptocurrency story. While other companies scrambled to catch the Bitcoin wave or jumped on the latest trend, this Colorado-based firm made a calculated bet that could reshape how institutional investors think about digital assets. In August 2025, CEA Industries completed a massive $500 million private placement specifically earmarked for one purpose: building the world's largest corporate treasury of BNB tokens. The company immediately signaled its commitment by changing its ticker symbol from VAPE to BNC, reflecting its new identity as the premier publicly traded gateway to the BNB ecosystem. But what exactly is BNB? Think of it as the fuel that powers one of the world's busiest blockchain networks. BNB (originally called Binance Coin) is the native cryptocurrency of the BNB Chain ecosystem, which processes millions of transactions daily for everything from trading and payments to smart contracts and decentralized applications. Unlike Bitcoin, which primarily serves as digital gold, BNB has real-world utility baked into its design. Users can stake it to earn rewards, pay transaction fees at discounted rates, and participate in the growing decentralized finance (DeFi) ecosystem. Perhaps most importantly, BNB features a quarterly "auto-burn" mechanism that permanently removes tokens from circulation, creating built-in scarcity that could benefit long-term holders. Here's where CEA Industries gets interesting. The company didn't just raise money and hope for the best. They assembled what might be the most impressive crypto-focused management team on Wall Street. David Namdar, co-founder of Galaxy Digital (one of the largest crypto investment firms), stepped in as CEO. Russell Read, former Chief Investment Officer at CalPERS (managing over $400 billion in assets) and Deputy CIO of Deutsche Bank Asset Management, joined as CIO. The board welcomed Hans Thomas, founding partner of 10X Capital, the firm managing BNC's treasury strategy. This isn't a group of crypto newcomers making speculative bets. These are seasoned financial professionals who've managed billions of dollars and understand institutional-grade risk management. The results speak for themselves. In August 2025, BNC announced the purchase of 200,000 BNB tokens worth approximately $160 million, officially making it the largest corporate holder of BNB globally. This wasn't just a headline grab—it demonstrated the company's ability to execute on its strategy quickly and at scale. The timing appears strategic. While BNB consistently ranks among the top five cryptocurrencies by market capitalization, most U.S. investors still can't buy it directly through traditional brokerage accounts. CEA Industries recognized this gap and positioned itself as the solution, offering regulated, SEC-compliant access to BNB exposure without the complexity of crypto wallets or exchange accounts. The company's financial backing adds credibility to its mission. The $500 million raise attracted over 140 institutional and crypto-native investors, including Pantera Capital, Arche Capital, ExodusPoint Capital Management, and Cantor Fitzgerald & Co. served as lead financial advisor, bringing Wall Street expertise to the strategy. What sets BNC apart from other crypto treasury companies is its singular focus. While competitors diversify across multiple digital assets, CEA Industries made an all-in bet on BNB Chain's ecosystem growth. The company believes this focused approach will allow it to capture maximum value as institutional adoption accelerates. The potential upside follows historical patterns. When MicroStrategy adopted Bitcoin as its primary treasury asset in 2020, the stock gained nearly 2,000% at its peak. Similar treasury strategies by companies like Janover (Solana) and MetaPlanet (Bitcoin) produced dramatic stock price moves following their announcements. CEA Industries has positioned itself to potentially benefit from this same dynamic, but with an asset that powers one of the most active blockchain ecosystems on Earth. With plans to deploy the remaining treasury capital and potential access to an additional $750 million through warrant exercises, BNC appears built for the long game in an ecosystem that's just getting started. BIT Mining Limited (NYSE: BTCM) announced its strategic expansion into the Solana ecosystem on July 10, 2025, marking a significant shift from traditional Bitcoin mining to building a robust SOL treasury worth up to $300 million. "While we continue to make progress in our crypto mining operations, we have strategically shifted our focus to actively explore opportunities within the Solana ecosystem," remarked Mr. Xianfeng Yang, CEO of BIT Mining."This move reflects our commitment to capturing broader market potential and aligning with emerging trends that can drive long-term value and growth for the Company." The cryptocurrency mining company plans to raise between $200-300 million in phases to convert existing crypto holdings into SOL tokens while also operating validator nodes to support network decentralization and earn staking rewards. This strategic transformation positions BIT Mining to capture emerging opportunities in the rapidly growing Solana blockchain ecosystem, leveraging its existing infrastructure and technical expertise to create sustainable shareholder value. Upexi, Inc. (NASDAQ: UPXI) announced it surpassed 2 million SOL tokens in its treasury as of August 4, 2025, representing a massive 172% increase from 735,692 SOL at the end of June following a $200 million capital raise. "July was a game-changing month for Upexi, particularly with respect to accretive capital raises and a resulting drastic increase in our Solana treasury," said Allan Marshall, CEO of Upexi. "During the month, we raised over $200 million and grew our Solana holdings by over 172% to 2 million SOL. And we continued to generate additional value for shareholders via an estimated 8% staking yield and additional purchases of discounted locked Solana." The brand owner turned crypto treasury company now holds approximately $334 million worth of Solana tokens, with substantially all coins being staked to earn roughly 8% annual yield, generating about $65,000 per day in revenue. Upexi has positioned itself as a pure-play Solana investment vehicle for public market investors, trading at attractive valuations relative to its underlying SOL holdings while benefiting from built-in gains through purchasing locked SOL at discounted prices. Bitcoin Depot Inc. (NASDAQ: BTM) reported strong Q2 2025 financial results on August 12, 2025, with revenue growing 6% year-over-year to $172.1 million and net income surging 183% to $12.3 million driven by expanded kiosk deployment and higher transaction volumes. The leading Bitcoin ATM operator, which operates over 8,800 kiosk locations across 47 states, significantly improved profitability with Adjusted EBITDA jumping 46% to $18.5 million while strengthening its balance sheet to nearly $60 million in cash and digital assets. "With nearly $60 million in cash and digital assets, we are well-positioned to capitalize on growth opportunities, both in the U.S. and internationally," said Brandon Mintz, Founder and CEO of Bitcoin Depot. "Looking ahead, we remain focused on scaling efficiently and delivering sustained value for our customers and shareholders." Bitcoin Depot also strategically added to its Bitcoin treasury holdings, bringing total Bitcoin reserves to 100.35 BTC, while simplifying its corporate structure and providing guidance for continued high-single-digit revenue growth in Q3 2025. Canaan Inc. (NASDAQ: CAN) reported July 2025 production results showing the Bitcoin mining company mined 89 bitcoins during the month while increasing its total Bitcoin holdings to 1,511 BTC as part of its newly adopted cryptocurrency holding policy. "We're pleased to report quarter-over-quarter improvement in our bitcoin mining performance, with monthly production resulting in 89 bitcoins, driven by a stronger bitcoin price and lower average power costs," said Nangeng Zhang, Chairman and CEO of Canaan. "In line with our recently announced Cryptocurrency Holding Policy, we retain bitcoins acquired through our daily operations as a long-term reserve asset. This policy allows us to accumulate bitcoin, and our total holdings at month-end were 1,511 bitcoins." The mining hardware manufacturer and operator faced some operational challenges with deployed hashrate declining to 7.95 EH/s and operating hashrate at 6.24 EH/s, primarily due to planned exits from underperforming hosting sites in favor of better-performing partners. Canaan continues to strengthen its position in the mining industry with recent major orders from public mining companies like Cipher Mining and CleanSpark, while maintaining operations across multiple regions including America, Kazakhstan, and other international locations. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Equity Insider on behalf of Market IQ Media Group Inc. ("MIQ"). MIQ has been paid a fee for CEA Industries Inc. advertising and digital media from Creative Digital Media Group ("CDMG"). There may be 3rd parties who may have shares of CEA Industries Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY does not own any shares of CEA Industries Inc. but reserve the right to buy and sell, and will buy and sell shares of CEA Industries Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved on behalf of CEA Industries Inc. by CDMG; this is a paid advertisement, we currently own shares of CEA Industries Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
